EN DE
Watch Procept Biorobotics Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Procept Biorobotics Corp (PRCT) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Procept Biorobotics Corp stock $18.25, price $22.37, that is 18.4% below the price, quality 45 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PB Procept Biorobotics Corp logo Thin data Nov 10, 2026

Procept Biorobotics Corp

PRCT · US
Expensive, weak quality

Our calculation puts a fair price 18% below what the stock costs today.

Low debt
Positive coverage
Revenue last quarter +19% vs. a year ago.
Quality 45/100
Expensive Growth (revenue 5y +109.0 %/yr in USD)
Insiders bought $498,315 (6M) · sold $143,184
Fair value $18.25 · Overvalued
Loss-making · -32.5% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 12/100
Thin data
Estimate
Watch Procept Biorobotics Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$99.45 $16.69 Fair Value $18.25 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $16.69 – $99.45 · fair‑value band $13.69 – $22.81 · the $22.37 price screens above the $18.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Procept Biorobotics in your weekly email

Every Wednesday you see whether Procept Biorobotics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.

Show moreShow less

It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.

The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.

PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Stock analysis

Procept Biorobotics Corp (PRCT) currently trades at $22.37, while our estimate is $18.25, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $13.69 (bear) to $22.81 (bull), the price of $22.37 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Procept Biorobotics Corp reported revenue of $308M in FY2025 versus $34.5M in FY2021, a compound +72.9%/yr. Reported net income was −$95.6M in FY2025.

Key figures

Market cap $1.3B Small · P/S ratio 3.65 · EPS (TTM) $−1.94 · Net margin −32.5% · Return on equity −30.2% · Return on assets (EBIT) −21.5% (5-year average) · Operating margin −32.1% · Revenue (TTM) $337M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 38% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at −18%, PRCT screens richer than that median.

Fair Value

Bear $13.69 Fair Value $18.25 Bull $22.81
Price $22.37 · Downside -18.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 82
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 35
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $498,315, on Aug 7, 2026. Over the same period, 4 people sold shares worth $143,184.

  • SalePooja SharmaChief Strat/Marketing Officer4,710 shares at $19.71$92,853Nov 6, 2026
  • SaleBarry L TemplinEVP, Chief Technology Officer2× since Jun 8, 2026: 731 shares, avg. $24.64$18,010Sep 9, 2026
  • SaleAlaleh NouriEVP, CLO, CORP. SEC.6× since Mar 6, 2026: 16,384 shares, avg. $24.94$408,665Sep 9, 2026
  • SaleKevin WatersEVP, CFO4× since Mar 6, 2026: 8,157 shares, avg. $24.17$197,143Sep 9, 2026
  • BuyLarry L WoodPresident, CEO, Director23,900 shares at $20.85$498,315Aug 7, 2026
  • BuyAntal Rohit DesaiDirector426,262 shares at $24.59$10.5MMar 9, 2026

Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+37.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+60.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+109.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+91.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−619.4% (2020) → −33.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PRCT screens overvalued: fair value 18% below the price. Compare with Abbott Laboratories, →

Recent news

News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Procept Biorobotics Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −18.4% · Below median
Profitability
Return on assets −18.8% · Below median
Net margin (12 months) −32.5% · Bottom 25%
Operating margin (12 months) −32.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 19.3% · Above median
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.46× · Pricier than median
P/S (12 months) 3.75× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 16
FUTURE (revenue growth)97 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)93 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥181.10 ¥202.57 +12% vs PRCT
Stryker Corporation SYK $325.73 $358.46 +10% vs PRCT
Boston Scientific Corporation BSX $44.02 $48.42 +10% vs PRCT
DexCom, Inc DXCM $81.07 $89.18 +10% vs PRCT
STERIS plc STE $256.94 $279.53 +9% vs PRCT
GE HealthCare Technologies Inc GEHC $84.03 $69.92 −17% vs PRCT
Edwards Lifesciences Corporation EW $104.71 $81.94 −22% vs PRCT
Abbott Laboratories, ABT $110.51 $75.28 −32% vs PRCT
Medtronic plc MDT $102.79 $65.61 −36% vs PRCT
Koninklijke Philips N.V PHIA €27.30 €15.23 −44% vs PRCT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Procept Biorobotics Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Procept Biorobotics Corp Fair Value". https://www.fairvalue-calculator.com/stock/PRCT

Frequently asked questions

Is Procept Biorobotics Corp (PRCT) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $18.25 versus a price of $22.37, about 18% lower (overvalued).
What is the fair value of PRCT?
Our estimate for Procept Biorobotics Corp is $18.25 (as of Nov 10, 2026), built from audited fundamentals. The current price: $22.37.
What is the quality score of PRCT?
Procept Biorobotics Corp has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Procept Biorobotics Corp (PRCT)?
Our calculated price target is the estimate of $18.25 (as of Nov 10, 2026). Cautious scenario $13.69, optimistic scenario $22.81. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Procept Biorobotics Corp stock forecast for 2026?
Our estimate puts fair value at $18.25, about 18% lower versus a price of $22.37 (overvalued). Cautious scenario $13.69, optimistic scenario $22.81. The calculation is refreshed regularly with new filings.
What is the revenue of Procept Biorobotics Corp (PRCT)?
Procept Biorobotics Corp reported trailing-twelve-month revenue of about $337M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Procept Biorobotics Corp (PRCT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Procept Biorobotics Corp it is $18.25 per share (as of Nov 10, 2026), against a price of $22.37.
Is Procept Biorobotics Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PRCT trades above its calculated fair value: price $22.37, fair value $18.25, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRCT?
No. The price is what the market pays today ($22.37); the fair value is what the company's own numbers justify ($18.25). For Procept Biorobotics Corp the two are $4.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Procept Biorobotics Corp worth?
The market values Procept Biorobotics Corp at about $1.3B (market capitalisation, as of Nov 10, 2026). Per share that is $22.37; our models calculate a fair value of $18.25 per share.
What do the bullish and bearish scenarios say about PRCT?
Our models span a range for Procept Biorobotics Corp: cautious scenario $13.69, base $18.25, optimistic $22.81 per share (as of Nov 10, 2026, price $22.37). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Procept Biorobotics Corp (PRCT)?
Balance-sheet figures for Procept Biorobotics Corp (as of Nov 10, 2026): return on equity −30.2%, debt of 0.14 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is PRCT from its 52-week high?
Procept Biorobotics Corp trades at $22.37, about 38% below its 52-week high of $36.10 and 34% above the low of $16.69 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $18.25 is for.
Which stocks are comparable to Procept Biorobotics Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Procept Biorobotics Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $22.37, calculated fair value $18.25 (−18%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Procept Biorobotics Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Procept Biorobotics Corp (PRCT)?
The closing price on Nov 9, 2026 was $22.37. Our estimate is $18.25, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Procept Biorobotics Corp right now?
Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Procept Biorobotics Corp

How large is the market capitalisation of Procept Biorobotics Corp (PRCT)?
The market capitalisation of Procept Biorobotics Corp is $1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Procept Biorobotics Corp (PRCT)?
The price-to-sales ratio of Procept Biorobotics Corp is 3.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Procept Biorobotics Corp (PRCT)?
Earnings per share at Procept Biorobotics Corp are $−1.94. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Procept Biorobotics Corp (PRCT)?
The net margin of Procept Biorobotics Corp is −32.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Procept Biorobotics Corp (PRCT)?
The return on equity (ROE) of Procept Biorobotics Corp is −30.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Procept Biorobotics Corp (PRCT)?
On an EBIT basis the return on assets of Procept Biorobotics Corp is −21.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Procept Biorobotics Corp (PRCT)?
The operating margin of Procept Biorobotics Corp is −32.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Procept Biorobotics Corp (PRCT)?
Revenue at Procept Biorobotics Corp is growing +19.3% versus a year earlier (3y avg +60.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Procept Biorobotics Corp (PRCT) generate?
The free cash flow of Procept Biorobotics Corp is −$58.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Procept Biorobotics Corp (PRCT) hold?
Procept Biorobotics Corp holds more cash than debt, $235M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Procept Biorobotics Corp in the live analysis

One click puts Procept Biorobotics Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.